Dodecanoate

Dodecanoate

SCHEMBL7187961

CCCCCCCCCCCC(=O)NC(C)C(N)=O.CCCCCCCCCCCC(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPK1 P28482 1/20 0.59
PLA2G10 O15496 2/20 0.58
PLA2G2C Q5R387 1/20 0.56
GPR84 Q9NQS5 7/20 0.55
PPARG P37231 7/20 0.55
PPARD Q03181 7/20 0.55
PPARA Q07869 7/20 0.55
HDAC11 Q96DB2 5/20 0.55
TSHR P16473 4/20 0.55
PTPN1 P18031 3/20 0.55
ALDH1A1 P00352 2/20 0.55
TLR2 O60603 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
FABP4 P15090 2/20 0.55
SLC22A6 Q4U2R8 1/20 0.55
SLC22A8 Q8TCC7 1/20 0.55
ESR1 P03372 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9665588 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL9666323 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL9664202 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL9666241 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL21587875 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL9666209 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL27326829 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL7519265 0.93 FAAH (0.67) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL9666212 0.92 FAAH (0.63) FAAHMEN1KMT2AMAPK1PLA2G10
SCHEMBL5983514 0.92 FAAH (0.63) FAAHMEN1KMT2AMAPK1PLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition L'OREAL (FR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition PLIN3, CUTA, FABP4 FAAH 159/4885MEN1 3234/4885KMT2A 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.